six years after announce your clinical trialsNeuroEpo, a drug against Alzheimer’s developed by Cuba, is still being tested in a study with around 300 people throughout the Island.
One of the places where it is carried out is at the Camilo Cienfuegos hospital, with 30 patients, according to reports this Monday. the provincial press. The drug has been tested since February in phase III in patients with mild or moderate Alzheimer’s, “amnesic variant”.
More than 60 patients had been examined to participate in the trial in Sancti Spíritus, but, he declared to Escambray Iralys Benítez Guzmán, provincial coordinator of Clinical Trials, “the 35 subjects that have been excluded from the study is because they do not meet the criteria, because, for example, they take drugs that were already approved to treat Alzheimer’s or have associated diseases or are in very advanced degrees of the disease”.
Although it has been in studies for years, NeuralEpo was approved in March 2022 by the Cuban regulatory agency, the Center for State Control of Medicines (Cecmed).
Although it has been in studies for years, NeuralEpo was approved in March 2022 by the Cuban regulatory agency, the Center for State Control of Medicines (Cecmed). Its objective is not to cure the disease, but to delay its process in those who suffer from it in a mild or moderate way.
The Cuban government reports from time to time on the progress of this drug with habitual triumphalism. In 2021, for example, the Presidency already communicated that a “phase II-III clinical trial” was giving “encouraging results.” On that occasion, treatment with NeuroEpo for 48 weeks “was safe and well tolerated” and “many of the patients showed a reduction in the progression of cognitive impairment and secondary variables also improved.”
The medicine, the authorities have explained, is the work of the Center for Molecular Immunology (CIM) – and hence its trade name, NeuralCIM – in collaboration with other BioCubaFarma institutions. It is a nasal formulation of a “recombinant low sialic acid” Erythropoietin (Epo) molecule, similar in composition to natural Epo produced in the central nervous system, which could help slow down neurodegenerative diseases.
An investigation carried out in 2017 estimated that 160,000 people on the Island living with dementia and that the figure would be 300,000 by the year 2040 (2.7% of the population).
________________________
Collaborate with our work:
The team of 14ymedio He is committed to doing serious journalism that reflects the reality of deep Cuba. Thank you for accompanying us on this long road. We invite you to continue supporting us, but this time becoming a member of our newspaper. Together we can continue transforming journalism in Cuba.
